Comparative efficacy and safety of first-line therapies for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis.
Anti-PD-1 immunotherapy combined with chemotherapy shows the strongest evidence as a first-line treatment for advanced gastric cancers lacking HER2.
This PubMed-indexed study examined comparative efficacy and safety of first-line therapies for advanced her2-negative gastric or gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis. Within the trial populations represented in this network, anti-PD-1 therapy plus doublet chemotherapy is the best-supported first-line chemoimmunotherapy strategy The analysis cannot determine CPS-specific effects, and favorable ACT rankings require confirmation before clinical application.
What the study was
- Study design
- Systematic review and network meta-analysis
- Population
- Human participants or human evidence described in the PubMed abstract
- Sample size
- 347
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Critical reviews in oncology/hematology
Why it surfaced
Systematic review and network meta-analysis with PubMed abstract evidence; scored conservatively for treatment innovation relevance and evidence maturity.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.